Turning cold tumors hot: from molecular mechanisms to clinical applications

J Zhang, D Huang, PE Saw, E Song - Trends in immunology, 2022 - cell.com
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Intratumoral heterogeneity in cancer progression and response to immunotherapy

I Vitale, E Shema, S Loi, L Galluzzi - Nature medicine, 2021 - nature.com
Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …

Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity

PMK Westcott, F Muyas, H Hauck, OC Smith… - Nature Genetics, 2023 - nature.com
DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …

Tumor mutational burden as a predictive biomarker in solid tumors

D Sha, Z Jin, J Budczies, K Kluck, A Stenzinger… - Cancer discovery, 2020 - AACR
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

The updated landscape of tumor microenvironment and drug repurposing

MZ Jin, WL Jin - Signal transduction and targeted therapy, 2020 - nature.com
Accumulating evidence shows that cellular and acellular components in tumor
microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and …

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

D Chowell, SK Yoo, C Valero, A Pastore… - Nature …, 2022 - nature.com
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

Mutational signatures: emerging concepts, caveats and clinical applications

G Koh, A Degasperi, X Zou, S Momen… - Nature Reviews …, 2021 - nature.com
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …

Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

S Krishna, FJ Lowery, AR Copeland, E Bahadiroglu… - Science, 2020 - science.org
Adoptive T cell therapy (ACT) using ex vivo–expanded autologous tumor-infiltrating
lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact …

Beyond immune checkpoint blockade: emerging immunological strategies

SP Kubli, T Berger, DV Araujo, LL Siu… - Nature reviews Drug …, 2021 - nature.com
The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

M Chalabi, LF Fanchi, KK Dijkstra, JG Van den Berg… - Nature medicine, 2020 - nature.com
Abstract PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …